CRISPR Therapeutics AG stock page - price, fundamentals, dividends - iOCharts

CRSP

100.26
+4.05 (4.21%)
CRISPR Therapeutics AG (NASDAQ, USD)
Healthcare >
Biotechnology
Market cap
7.60B
Ent value
6.62B
Price/Sales
10565.49
Price/Book
4.21
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
54.00%
1 year return
-6.93%
3 year return
36.13%
5 year return
-
10 year return
-
Last updated: 2021-10-19

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open97.47
Daily high102.96
Daily low97.34
Daily Volume1.90M
All-time high210.04
1y analyst estimate158.83
Beta2.25
EPS (TTM)-4.72
Dividend per share-
Ex-div date-
Next earnings date28 Oct 2021

Downside potential

Loading...
Downside potential data
CRSPS&P500
Current price drop from All-time high-52.27%-0.56%
Highest price drop-69.11%-56.47%
Date of highest drop21 Dec 20189 Mar 2009
Avg drop from high-27.07%-11.45%
Avg time to new high21 days12 days
Max time to new high520 days1805 days

DIVIDENDS

CRSP does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales10565.49
Price to Book4.21
EV to Sales9211.32

FINANCIALS

Per share

Loading...
Per share data
Current share count75.77M
EPS (TTM)-4.72
FCF per share (TTM)-3.56

Income statement

Loading...
Income statement data
Revenue (TTM)719.00K
Gross profit (TTM)719.00K
Operating income (TTM)-354.44M
Net income (TTM)-348.87M
EPS (TTM)-4.72
EPS (1y forward)-6.32

Margins

Loading...
Margins data
Gross margin (TTM)100.00%
Operating margin (TTM)-49295.55%
Profit margin (TTM)-48520.86%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash1.13B
Net receivables150.00K
Total current assets1.83B
Goodwill0.00
Intangible assets167.00K
Property, plant and equipment102.04M
Total assets1.96B
Accounts payable66.29M
Short/Current long term debt61.47M
Total current liabilities83.09M
Total liabilities152.41M
Shareholder's equity1.81B
Net tangible assets1.81B

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-238.37M
Capital expenditures (TTM)24.95M
Free cash flow (TTM)-263.32M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-20.96%
Return on Assets-19.08%
Return on Invested Capital-20.96%
Cash Return on Invested Capital-15.82%
COMPANY DETAILS
CRSP (CRISPR Therapeutics AG) company logo
Marketcap
7.60B
Marketcap category
Mid-cap
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, the company is developing allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. Further, it engages in the development of regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, Duchenne muscular dystrophy, myotonic dystrophy type 1, and cystic fibrosis. The company has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, and ViaCyte, Inc. It also has a strategic partnership with Nkarta, Inc. to research, develop, and commercialize CRISPR/Cas9 gene-edited cell therapies for cancer. The company was formerly known as Inception Genomics AG and changed its name to CRISPR Therapeutics AG in April 2014. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Employees
410
Investor relations
SEC filings
CEO
Samarth Kulkarni
Country
USA
City
Zug
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
October 19, 2021
In this article, we will take a look at the 11 best genomic stocks to buy now. If you want to skip our detailed analysis of these stocks, go directly to 5 Best Genomic Stocks to Buy Now. Genomics is a...
October 19, 2021
ARK Invest founder Cathie Wood doesn't mind going against the grain. Here are three beaten-down stocks Wood is buying that Wall Street thinks will skyrocket. Shares of Arcturus Therapeutics (NASDAQ:...
October 18, 2021
It looks like the gene therapy market is a haunted house, but growing biotech Repligen might be the treat investors need this Halloween.
October 17, 2021
They only have preclinical candidates for now. But these biotechs could have game-changing gene-editing therapies.
October 16, 2021
The healthcare sector has been a serious disappointment for investors in 2021. After a banner year in 2020 thanks to the advent of several highly lucrative COVID-19 vaccines and therapies, the closel...
October 16, 2021
CRISPR Therapeutics (NASDAQ: CRSP) is one of the most exciting biotechs on the market today, because it's pushing the limits of what is possible when it comes to treating hereditary diseases. As the ...
October 15, 2021
Shares of CRISPR Therapeutics AG (NASDAQ: CRSP) may be forming a “V” bottom on the chart. That means the stock could rally. V bottoms and V tops illustrate rapid reversals of a trend. A characteristic...
October 15, 2021
The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics
October 14, 2021
Here we discuss four biotech companies, CRSP, EDIT, SRPT and BEAM, that have the potential to gain from their promising gene therapy pipeline candidates.
October 14, 2021
ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ser...
Next page